These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16955198)

  • 21. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
    Tsai TF; Liu MT; Liao YH; Licu D
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.
    Jones BB; Millsop JW; Walsh JA; Krueger GG; Callis Duffin K
    Br J Dermatol; 2015 Jul; 173(1):272-4. PubMed ID: 25557081
    [No Abstract]   [Full Text] [Related]  

  • 26. Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management.
    Ulmer A; Wölbing F; Metzler G; Schanz S; Fierlbeck G; Röcken M
    Br J Dermatol; 2008 Apr; 158(4):867-9. PubMed ID: 18284393
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
    Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alopecia areata universalis elicited during treatment with adalimumab.
    Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
    Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
    Gordon KB; Ruderman EM
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S85-91. PubMed ID: 16488334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalized pustular psoriasis following withdrawal of efalizumab.
    Gaylor ML; Duvic M
    J Drugs Dermatol; 2004; 3(1):77-9. PubMed ID: 14964752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris.
    Antoniou C; Dessinioti C; Katsambas A; Stratigos AJ
    Br J Dermatol; 2007 May; 156(5):1090-1. PubMed ID: 17408391
    [No Abstract]   [Full Text] [Related]  

  • 33. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 37. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arthritis in patients with psoriasis treated with gamma-interferon.
    O'Connell PG; Gerber LH; Digiovanna JJ; Peck GL
    J Rheumatol; 1992 Jan; 19(1):80-2. PubMed ID: 1556705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
    Voulgari PV; Venetsanopoulou AI; Epagelis EK; Alamanos Y; Takalou I; Drosos AA
    Ann Rheum Dis; 2007 Feb; 66(2):270-1. PubMed ID: 17068063
    [No Abstract]   [Full Text] [Related]  

  • 40. Psoriasis vulgaris and arthritis psoriatica gravis mutilans.
    Vrzogić P; Pasić A; Podobnik-Takac T
    Acta Dermatovenerol Croat; 2003; 11(1):22-8. PubMed ID: 12718792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.